SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Georgetown, TX.

TSS Inc

TSS Inc. is seeing intense community discussion following a significant market reaction to its latest earnings report, which highlighted a intentional pivot away from low-margin procurement toward high-margin AI systems integration. While some investors are concerned by headline revenue declines and heavy short interest, others argue the sell-off is an overreaction that ignores strong fundamental growth in AI rack infrastructure and increasing executive alignment with major enterprise partners.

AIOZ Network is a DePIN for Web3 AI, Storage and Streaming.  AIOZ empowers a faster, secure and decentralized future.   Powered by a global network of DePINs,  AIOZ rewards you for sharing your computational resources for storing, transcoding, and streaming digital media content and powering decentralized AI computation.

AIOZ Network

AIOZ Network is trending as community members speculate on a potential breakout driven by its integration with NVIDIA and its role as a DePIN leader in AI, storage, and streaming. While some investors express frustration over price volatility, many are actively accumulating positions, drawing comparisons to previous explosive rallies and monitoring technical indicators for a move back toward significant resistance levels.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is trending amid a surge in institutional activity, highlighted by a strong inflow streak into new spot ETFs and ongoing discourse surrounding Ripple's expanded role in global payment infrastructure. While some in the community remain skeptical of recent price volatility, others are focused on long-term accumulation, anticipating that regulatory progress and institutional adoption will drive future growth.

MercadoLibre, Inc. engages in the development of an online commerce platform with a focus on e-commerce and related services. It operates through the following geographical segments: Brazil, Argentina, Mexico, and Other Countries. The Other Countries segment refers to Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, Bolivia, Honduras, Nicaragua, El Salvador, Guatemala, Paraguay, Uruguay, and the United States of America. Its products provide a mechanism for buying, selling, and paying as well as collecting, generating leads, and comparing lists through e-commerce transactions. The company was founded by Marcos Eduardo Galperin on October 15, 1999 and is headquartered in Montevideo, Uruguay.

MercadoLibre Inc

MercadoLibre is currently generating intense debate as it navigates a phase of heavy reinvestment into its logistics and fintech ecosystem, leading some investors to view current margin compression as a temporary hurdle for a long-term compounder while others express frustration over stagnant price performance. The community is actively weighing the potential for a breakout against the risks of short-term volatility, with many traders closely watching technical support levels ahead of upcoming earnings.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is experiencing a surge in community engagement driven by bullish sentiment regarding its potential for technical breakouts and broader integration within emerging financial ecosystems. Traders are actively debating the token's long-term utility versus its speculative nature, while monitoring broader market trends as the community pushes for increased adoption and momentum.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant (QNT) is trending as investors monitor its involvement in real-world tokenization projects, including central bank pilot programs and enterprise-grade interoperability solutions. Community sentiment is deeply divided between long-term holders anticipating a supply-driven breakout and traders frustrated by its stagnant price action relative to broader market performance.

Got that dog in you? - Fueled by a mantra of tokenized self-belief, doginme is representative of the community's collective efforts to embrace and embolden that dog in them. doginme stands for knowing yourself and having that unshakable drive to keep pushing forward. doginme was originally launched in February 2024 when the Farcaster founder was asked if he owned a dog, to which he replied affirmatively: "no but I got that dog in me"

doginme

DOGINME is trending as investors rally around its "tokenized self-belief" narrative and strong community-driven culture on the Base chain. Enthusiasts are actively debating its potential for explosive growth, often highlighting its low market cap and comparing its community's resolve to early-stage meme coin runs.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is seeing heightened investor activity as the community remains bullish on its privacy-focused utility and potential as a quantum-resistant alternative to Bitcoin. Traders are actively discussing technical breakouts and long-term price targets while debating the asset's role in a future dominated by increased surveillance and digital currency regulation.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is generating significant community buzz as traders closely watch for a breakout above key technical resistance levels, with many discussing its potential to re-accelerate alongside broader crypto market momentum. The conversation is heavily driven by retail sentiment, speculation on ecosystem strength, and hopes for a return to higher price tiers as market participants monitor for sustained bullish continuation.

BLOCKLORDS

BLOCKLORDS is drawing significant community attention due to its extremely low circulating supply and small market cap, which many traders believe makes the token highly sensitive to sudden, explosive price moves. Investors are actively discussing its potential for volatility and are tracking its performance against other low-cap gaming tokens, debating whether the current interest is a sustainable breakout or just another cycle of rapid pumps and dumps.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today...

Viridian Therapeutics (NASDAQ:VRDN) Given "Buy" Rating at Needham & Company LLC

Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 price target on shares of Viridian Therapeutics in a research report on Tuesday...

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

Promising Biotech Stocks To Watch Today - May 5th

Vertex Pharmaceuticals, Danaher, and Viridian Therapeutics are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that research, develop and commercialize biological products and technologiessuch as novel drugs, gene thera...

Viridian Therapeutics (NASDAQ:VRDN) Shares Gap Up  on Strong Earnings

Viridian Therapeutics (NASDAQ:VRDN) Shares Gap Up Following Earnings Beat...

<ul class="summary-bullets"><li>The therapy delivered proptosis response rates 50% at week 24 for dosing every four weeks, compared with 15% for placebo.</li><li>Viridian is expected to file an application for the therapy with the FDA by the first quarter of 2027.</li><li>Q1 loss came in at $0.90 per share, lower than Wall Street’s estimate of $1.08 per share, according to Fiscal.ai data.</li></ul>Shares of Viridian Therapeutics (VRDN) jumped more than 35% on Tuesday following strong late-stage results for its thyroid eye disease treatment and a better-than-feared first-quarter loss.<a href="https://stocktwits.com/symbol/VRDN">VRDN shares</a> recorded their biggest single-day gain since Aug. 15, 2022.<h2 class="st-heading-2">VRDN’s Elegrobart Shines In Phase 3 Trial</h2>Viridian said that Elegrobart, its Thyroid Eye Disease (TED) therapy, met its primary endpoint in the REVEAL-2 Phase 3 study, highlighting meaningful improvements across key measures in patients with chronic disease.The therapy delivered proptosis response rates (PRR) of 50% and 54% at week 24 for dosing every four and eight weeks, respectively, compared with 15% for placebo. The PRR is a measure of reduction in eye protrusion.The drug also showed benefits in reducing double vision, with the four-week group achieving a 61% diplopia response rate versus 38% in the placebo group. Elegrobart was generally well tolerated, with most side effects mild and in line with expectations for its drug class.Rates of hearing-related issues were low, and no treatment-related serious adverse events were reported. Notably, 91% of patients completed the full course of treatment. A regulatory filing with the U.S. Food and Drug Administration (FDA) remains on track for the first quarter (Q1) of 2027.<h2 class="st-heading-2">VRDN’s Q1 Loss Widens But Tops Estimates</h2>Viridian also reported its Q1 results on Tuesday. While its loss widened to $0.90 per share from $0.87 per share, it beat Wall Street’s estimate of $1.08 per share, according to Fiscal.ai data.Research and development (R&amp;D) expenses came in at $77.6 million for the quarter, edging up from $76.8 million a year ago, primarily driven by higher manufacturing-related costs.Viridian also added that its other TED therapy, Veligrotug, is under ‘Priority Review’ by the FDA, with a decision expected by June 30, 2026. The company has completed hiring its field teams and has its supply, manufacturing, and distribution systems ready for the launch.<h2 class="st-heading-2">Retail Sees VRDN’s Therapy Outperforming Amgen’s Tepezza</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘high’ message volumes.One user explained why Elegrobart could see better uptake than Amgen’s Tepezza.<stembedurl>https://stocktwits.com/Sjskdhai/message/652274493</stembedurl>Another user expects the stock to climb to at least $20 by the end of the session. It is currently at $19.<stembedurl>https://stocktwits.com/Drugtrade/message/652281724</stembedurl>The stock has declined more than 40% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-immunitybio-aua-meeting-anktiva-bcg-data-next-week/cZQwCMWRe9R">IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

VRDN Stock Records Biggest Single Day Gains In 45 Months – And It’s Not Just Due To A Better-Than-Feared Q1 Loss

Viridian said that Elegrobart, its Thyroid Eye Disease therapy, met its primary endpoint in the REVEAL-2 Phase 3 study.

Equity

Markets On Fire: Biotech Breakthroughs and AI Mega-Deals Move Wall Street

$CLRB, $NTHI, $BLZE, $DGXX, $VRDN, $CYTK are among today's leading stocks

Viridian Therapeutics (NASDAQ:VRDN) Issues Earnings Results

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.16. Viridian Therapeutics had a negative return on equity of 83.25% and a...

Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the first quarter ended March 31...

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have received a consensus rating of "Moderate Buy" from the fifteen research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned...

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

VRDN
Viridian Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest VRDN News

VRDNViridian Therapeutics Inc